Company intelligence / Profile preview

Vohesu

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Vohesu is an early-stage biotechnology company focused on developing next-generation gene therapies for the treatment of severe genetic and rare diseases. The company leverages a proprietary platform designed to enhance the precision and efficiency of genetic modifications within the human genome. While currently operating in a relatively quiet phase, Vohesu aims to address significant unmet medical needs by targeting the underlying molecular causes of chronic conditions. Its research and development efforts are centered on creating durable, one-time curative treatments through innovative genomic medicine approaches.

Therapeutic areas: Rare Diseases
Modalities: Gene therapySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Vohesu.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vohesu.

Explore the full profile